Overview

Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study

Status:
Active, not recruiting

Trial end date:
2032-05-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, single arm, phase II study evaluating the efficacy of image-guided de-escalating neoadjuvant treatment with paclitaxel, Herceptin® (trastuzumab), carboplatin, and pertuzumab (PTC-Ptz) in stage II-Ill HER2-positive breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Borstkanker Onderzoek Groep

Collaborators:

BOOG Study Center
BOOG Study Center, coordinating center of Borstkanker Onderzoek Groep
Roche Pharma AG